Article PDF first page preview

First page of Efficacy of cognitive behavioral therapy and acceptance- and mindfulness-based treatments in adults with bodily distress – a network-meta-analysis

Introduction: Many physical complaints cause long-term bodily distress. Meta-analyses show that cognitive behavioral therapy (CBT) and acceptance- and mindfulness-based treatments (AMBT) reduce somatic symptom severity, but evidence on differential efficacy is limited. Objective: This study evaluates the efficacy of CBT and AMBT for bodily distress (e.g., somatoform disorders, functional somatic syndromes, and related disorders). Methods: A network meta-analysis of randomized controlled trials on adults with bodily distress compared CBT and AMBT either directly or with non-specific control groups. Cohen’s d based on between-group effect sizes was aggregated using a random effects model. Primary outcome was somatic symptom severity; secondary outcomes included depression, anxiety, and perceived health status. Results: Based on 74 studies (N = 8,277), CBT (d = -0.50, 95%CI -0.70 to -0.29; between-group effect sizes vs. wait-list) and AMBT (d = -0.55, 95%CI -1.06 to -0.23; between-group effect sizes vs. wait-list) were equally effective in reducing somatic symptoms at post-treatment. AMBT were more effective than CBT in reducing depression (d = -0.31, -0.58 to -0.04; between-group effect sizes) and anxiety (d = -0.42, -0.73 to -0.11; between-group effect sizes) post-treatment. At long-term follow-up, effects were partly maintained; AMBT remained more effective than CBT for anxiety, with no differential effects for other outcomes. Conclusions: Both treatments showed benefits compared to various controls. Evidence suggests potential differential treatment effects, indicating some patient groups may benefit more from AMBT. Clinicians should view CBT as foundational but remain open to variations, especially for comorbid pathology.

Journal Section:
Innovations
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution 4.0 International License .
Attribution